Le Lézard
Classified in: Business
Subject: ATY

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Proteostasis Therapeutics, Inc. - PTI


NEW YORK, March 20, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Proteostasis Therapeutics, Inc. ("Proteostasis" or the "Company") (NASDAQ: PTI).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

The investigation concerns whether Proteostasis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On March 20, 2018, Kerrisdale Capital Management published a report entitled "Proteostasis Therapeutics, Inc.: Hyped-Up Lung Data? Just a Lot of Hot Air."  The report asserted that in the Phase 2 study for the Company's cystic-fibrosis drug, PTI-428, "the placebo group's small size and anomalously bad outcomes misleadingly make the treatment group's unimpressive results look good by comparison."  Accordingly, the report concluded that the drug "is ineffective and will likely fail future Phase 3 trials."  On this news, Proteostasis's share price has fallen sharply during intraday trading on March 20, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected] 
888-476-6529 ext. 9980

 

SOURCE Pomerantz LLP


These press releases may also interest you

at 05:20
Engel & Völkers Florida today announced the outstanding achievement of Michael Ledwitz, Broker/Owner of Engel & Völkers Boca Raton, who has been recognized as the Top Advisor in GCI for his outstanding performance in 2023. This prestigious accolade...

at 05:05
Building upon its recent success in revamping its indices product offering, leading CFD broker Vantage Markets ("Vantage") is thrilled to announce the introduction of enhanced website features and app enhancements, further solidifying its position as...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 05:00
AM...

at 05:00
36Kr Holdings Inc. ("36Kr" or the "Company" or "We") , a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended...

at 05:00
Media are invited to join Kody Blois, Member of Parliament for Kings-Hants, on behalf of the Honourable Sean Fraser, Minister of Housing, Infrastructure and Communities, and Eleanor Roulston, Warden of the Municipality of East Hants, for a housing...



News published on and distributed by: